Effect of PVP K30 and/or L-arginine on stability constant of etoricoxib-HPβCD inclusion complex: Preparation and characterization of etoricoxib-HPβCD binary system

Drug Development and Industrial Pharmacy

Volumn 35, Issue 1, 2009, Pages 118-129

  Shah, Manali ^a   Karekar, Poonam ^a   Sancheti, Pankajkumar ^a   Vyas, Vikrant ^a   Pore, Yogesh ^a  

^a Government College of Pharmacy   (India)

Author keywords

1HNMR; Dissolution rate; Etoricoxib; HP CD; Phase solubility; Stability constant

Indexed keywords

2 HYDROXYPROPYL BETA CYCLODEXTRIN; ARGININE; ETORICOXIB; POVIDONE DERIVATIVE; POVIDONE K30; UNCLASSIFIED DRUG;

ARTICLE; COMPLEX FORMATION; DRUG SOLUBILITY; DRUG STABILITY; FREEZE DRYING; ROOM TEMPERATURE;

ARGININE; BETA-CYCLODEXTRINS; CYCLOOXYGENASE INHIBITORS; DRUG STABILITY; EXCIPIENTS; FREEZE DRYING; MAGNETIC RESONANCE SPECTROSCOPY; POVIDONE; PYRIDINES; SOLUBILITY; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; SULFONES; X-RAY DIFFRACTION;

EID: 56749131782     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.1080/03639040802220292     Document Type: Article

References (53)

1. Acartürk, F., Kişlal, Ö., & Çelebi, N. (1992). The effect of some natural polymers on the solubility and dissolution characteristics of nifedipine. Int. J. Pharm., 85, 1-6.
2. Agrawal, N. G. B., & Porras, A. G. (2001). Dose proportionality of oral etoricoxib, a highly selective cyclooxygenase-2 inhibitor, in healthy volunteers. J. Clin. Pharmacol., 41, 1106-1110.
3. Ali, S. M., Asmat, F., Maheshwari, A., & Koketsu, M. (2005). Complexation of fluoxetine hydrochloride with β-cyclodextrin. A proton magnetic resonance study in aqueous solution. Il Farmaco, 60, 445-449.
4. Ali, S. M., Maheshwari, A., & Asmat, F. (2004). Complexation of roxatidine acetate hydrochloride with β-cyclodextrin; NMR spectroscopic study. Pharmazie, 8, 653-655.
5. Bergaron, R. J., & Rowan, R. (1976). The molecular disposition of sodium p-nitrophenolate in the cavities of cycloheptaamylose and cyclohexaamylose in solution. Bioorg. Chem., 5, 423-436.
6. Berge, S., Bighley, L., & Monkhouse, D. C. (1977). Pharmaceutical salts. J. Pharm. Sci., 66, 1-19.
7. Bettinetti, G. P., Gazzania, A., Mura, P., Giordano, F., & Setti, M. (1992). The thermal behaviour and dissolution properties of naproxen in combinations with chemically modified β-cyclodextrins. Drug Dev. Ind. Pharm., 18, 39-53.
8. Bettinetti, G. P., Melani, F., Mura, P., Monnanni, R., & Giordano, F. (1991). Carbon-13 nuclear magnetic resonance study of naproxen interaction with cyclodextrin in solution. J. Pharm. Sci., 80, 1162-1169.
9. Brewster, M. E., & Loftsson, T. (2007). Cyclodextrins as pharmaceutical solubilizers. Adv. Drug Deliv. Rev., 59, 645-666.
10. Cappello, B., Carmignani, C., Iervolino, M., Immacolata la Rotonda, M., & Saettone, M. F. (2001). Solubilization of tropicamide by hydroxypropyl-β-cyclodextrin and water-soluble polymers: In vitro: In vivo studies. Int. J. Pharm., 213, 75-81.
11. Chen, C., Chen, F., Wu, A., Hsu, H., Kang, I., & Cheng, H. (1996). Effect of hydroxypropyl-β-cyclodextrin on the solubility, photostability and in vitro permeability of alkannimshikonin enantiomers. Int. J. Pharm., 141, 171-178.
12. Cirri, M., Maestrelli, F., Corti, G., Furlanetto, S., & Mura, P. (2006). Simultaneous effect of cyclodextrin complexation, pH, and hydrophilic polymers on naproxen solubilization. J. Pharm. Biomed. Anal., 42, 126-131.
13. Cochrane, D. J., Jarvis, B., & Keating, G. M. (2002). Etoricoxib. Drugs, 62, 2637-2651.
14. Dollo, G., Corre, P., Chollet, M., Chevanne, F., Bertault, M., Burgot, J., & Verge, R. (1999). Improvement in solubility and dissolution rate of 1,2-dithiole-3-thiones upon complexation with β-cyclodextrin and its hydroxypropyl and sulfobutyl ether-7 derivatives. J. Pharm. Sci., 88, 889-895.
15. Erden, N., & Celebi, N. (1988). A study of inclusion complex of naproxen with β-cyclodextrin. Int. J. Pharm., 48, 83-89.
16. Esclusa-Diaz, M. T., Gayo-Otero, M., Perez-Marcos, M. B., Vila-Jato, J. L., & Torres-Labandeira, J. J. (1996). Preparation and evaluation of ketoconazole-β-cyclodextrin multicomponent complexes. Int. J. Pharm., 142, 183-187.
17. Fenyvesi, E., Vikmon, M., SzemanSzejtli, J. J., Ventura, P., & Pasini, M. (1994). In T. Osa (Ed.), Enhancement of drug solubilizing capacity of hydroxy-propyl-β-cyclodextrin by tertiary complex formation. Proceeding of Seventh International Symposium on Cyclodextrins (pp. 414-418). Tokyo: Academic Society of Japan.
18. Fernandes, C. M., Vieira, M. T., & Veiga, F. J. B. (2002). Physicochemical characterization and in vitro dissolution behavior of nicardipine-cyclodextrins inclusion compounds. Eur. J. Pharm. Sci., 15, 79-88.
19. Ford, J. L. (1986). The current status of solid dispersions. Pharm. Acta Helv., 61, 69-88.
20. Fromming, K. H., & Szejtli, J. (1994). Cyclodextrins in pharmacy. Dordrecht: Kluwer Academic.
21. Goldberg, A. H., Gribaldi, M., Kanig, J. L., & Myersohn, M. (1966). Increasing dissolution rates and gastrointestinal absorption of drugs IV: Chloramphenicol-urea system. J. Pharm. Sci., 55, 1205-1211.
22. Higuchi, T., & Connors, K. A. (1965). Phase-solubility techniques. Adv. Anal. Chem. Instrum., 4, 117-212.
23. Ismail, S. (1991). Interaction of anti-convulsant drugs with alpha and betacyclodextrins I. Methsumide. STP Pharm. Sci., 1, 321-325.
24. Khan, K. A. (1975). The concept of dissolution efficiency. J. Pharm. Pharmacol., 27, 48-49.
25. Laveneziana, D., Speranza, R., Raulli, P., & Paredi, G. (1996). Ibuprofenarginine in the management of pain. Clin. Drug. Investig., 11, 1-7.
26. Lazaro, G. S., Ferreira, O. P., & Gimeneza, I. F. (2007). Inclusion complexes of pyrimethamine in 2-hydroxypropyl-β-cyclodextrin: Characterization, phase solubility and molecular modeling. Bioorg. Med. Chem., 15, 5752-5759.
27. Lin, S., & Kao, Y. (1989). Solid particulates of drug-β- cyclodextrin inclusion complexes directly prepared by a spray-drying technique. Int. J. Pharm., 56, 249-259.
28. Loftsson, T., & Fridriksdóttir, H. (1998). The effect of water-soluble polymers on the aqueous solubility and complexing abilities of β-cyclodextrin. Int. J. Pharm., 163, 115-121.
29. Loftsson, T., Fridriksdóttir, H., & Gudmundsdóttir, T. K. (1996). The effect of water-soluble polymers on aqueous solubility of drugs. Int. J. Pharm., 127, 293-296.
30. Loftsson, T., Hreinsdottir, D., & Masson, M. (2005). Evaluation of cyclodextrin solubilization of drugs. Int. J. Pharm., 302, 18-28.
31. Longxiao, L., & Suyan, Z. (2006). Preparation and characterization of inclusion complexes of prazosin hydrochloride with β-cyclodextrin and hydroxypropyl-β-cyclodextrin. J. Pharm. Biomed. Anal., 40, 122-127.
32. Moyano, J., Arias-Blanco, M., Ginés, J., & Giordano, F. (1997). Solid-state characterization and dissolution characteristics of gliclazide-β-cyclo-dextrin inclusion complexes. Int. J. Pharm., 148, 211-217.
33. Mulinacci, N., Melani, F., Mazzi, G., & Vincieri, F. (1993). Molecular modelling and NMR NOE experiments: Complementary tools for the investigation of complex ibuproxam-β-cyclodextrin topology. Int. J. Pharm., 90, 35-41.
34. Mura, P., Bettinetti, G. P., Cirri, M., Maestrelli, F., Sorrenti, M., & Catenacci, L. (2005). Solid-state characterization and dissolution properties of naproxen-arginine-hydroxypropyl-β-cyclodextrin ternary system. Eur. J. Pharm. Biopharm., 59, 99-106.
35. Mura, P., Bettinetti, G. P., Manderioli, A., Faucci, M. T., Bramanti, G., & Sorrenti, M. (1998). Interactions of ketoprofen and ibuprofen with β-cyclodextrins in solution and in the solid state. Int. J. Pharm., 166, 189-203.
36. Mura, P., Faucci, M. T., & Bettinettib, G. P. (2001a). The influence of polyvinylpyrrolidone on naproxen complexation with hydroxypropyl-β- cyclodextrin. Eur. J. Pharm. Sci., 13, 187-194.
37. Mura, P., Faucci, M. T., Manderioli, A., & Bramanti, G. (2001b). Multicomponent systems of econazole with hydroxyacids and cyclodextrins. J. Incl. Phenom., 39, 131-138.
38. Nakajima, T., Sunagawa, M., Hirohashi, T., & Fujioka, K. (1984). Studies of cyclodextrin inclusion complexes. I. Complex between cyclodextrin and bencyclane in aqueous solution. Chem. Pharm. Bull. (Tokyo), 32, 400-483.
39. Nishijo, J., Ushiroda, Y., Ohbori, H., Sugiura, M., & Fujii, N. (1997). The interaction of 1-naphthalene sulfonate with/β-cyclodextrin: Studies by calorimetry and proton nuclear magnetic resonance spectroscopy. Chem. Pharm. Bull., 45, 899-903.
40. Redenti, E., Szente, L., & Szejtli, J. (2000). Drug/cyclodextrin/ hydroxy acid multicomponent systems. Properties and pharmaceutical applications. J. Pharm. Sci., 89, 1-8.
41. Rekharsky, M. V., Goldberg, R. N., Schwarz, F. Z., Tewari, Y. B., Ross, P. D. Yamashoji, Y., & Inoue, Y. (1995). Thermodynamic and nuclear magnetic resonance study of the interactions of α- and β-cyclodextrin with model substances, phenethylamine, ephedrines, and related substances. J. Am. Chem. Soc., 117, 8830-8840.
42. Ribeiro, L., Loftsson, T., Ferreira, D., & Veiga, F. (2003). Investigation and physicochemical characterization of vinpocetine-sulfobutyl ether β-cyclodextrin binary and ternary complexes. Chem. Pharm. Bull., 51, 914-922.
43. Rodrigues, A. D., Halpin, R. A., & Geer, L. A. (2003). Absorption, metabolism, and excretion of etoricoxib, a potent and selective cyclooxygenase-2 inhibitor, in healthy male volunteers. Drug Metab. Dispos., 31, 224-232.
44. Ryan, J. A. (1986). Compressed pellet X-ray diffraction monitoring for optimisation of crystallinity in lyophilised solids: Imipenem: Cilastatin sodium case. J. Pharm. Sci., 75, 805-807.
45. Schneider, H. J., Hacket, F., Rudiger, V., & Ikeda, H. (1998). NMR studies of cyclodextrins and cyclodextrin complexes. Chem. Rev., 98, 1755-1786.
46. Szente, L., & Szejtli, J. (1999). Highly soluble cyclodextrin derivatives: Chemistry, properties, and trends in development. Adv. Drug Deliv. Rev., 36, 17-28.
47. Thompson, D. O. (1997). Cyclodextrins-enabling excipients: Their present and future use in pharmaceuticals. In D. O. Thompson (Ed.), Critical reviews in therapeutic drug carrier systems (pp. 1-104). CT, USA: Begell House.
48. Uekama, K., Hirayama, F., & Irie, T. (1998). Cyclodextrin drug carrier systems. Chem. Rev., 98, 2045-2076.
49. Usui, F., Maeda, K., Kusai, A., Nishimura, K., & Yamamoto, K. (1997). Inhibitory effects of water-soluble polymers on precipitation of RS-8359. Int. J. Pharm., 154, 59-66.
50. Valero, M., Perez-Revuelta, B. I., & Rodriguez, L. J. (2003). Effect of PVP K-25 on the formation of the naproxen: β-cyclodextrin complex. Int. J. Pharm., 253, 97-110.
51. Veiga, F. J. B., Ribeiro, L. S. S., & Ferreira, D. C. (2003). Physicochemical investigation of the effects of water-soluble polymers on vinpocetine complexation with β-cyclodextrin and its sulfobutyl ether derivative in solution and solid state. Eur. J. Pharm. Sci., 20, 253-266.
52. Veiga, F. J. B., Teixeira-Dias, J. J. C., Kedzierewicz, F., Sousa, A., & Maincent, P. (1996). Inclusion complexation of tolbutamide with β-cyclodextrin and hydroxypropyl-β-cyclodextrin. Int. J. Pharm., 129, 63-71.
53. Vikmon, M., Szeman, J., Szejtli, J., Pasini, M., Redenti, E., & Ventura, P. (1994). In T. Osa (Ed.), Terfenadine/hydroxy acid/cyclodextrin complexes. Proceedings of Seventh International Symposium on Cyclodextrin (pp. 480-483). Tokyo: Academic Society of Japan.